Efficacy of combination immunotherapy of IgM MAb B6.1 and amphotericin B against disseminated candidiasis

Ye, Han

doi:10.1016/j.intimp.2010.08.027

Cited by 15 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of this immunoprophylaxis can be augmented when used in combination with conventional antifungal therapy, as it has been shown with Mycograb and amphotericin B (Amp B) in patients with invasive candidiasis (44). MAb B6.1 also was demonstrated to enhance the therapeutic efficacy of Amp B, which may lead to a reduction of the amount of the antifungal agent needed for treatment to nontoxic levels (24).…”

Section: Vol 18 2011 Vaccine and Antibody Protection Against Candidmentioning

confidence: 99%

See 1 more Smart Citation

Vaccine and Monoclonal Antibody That Enhance Mouse Resistance to Candidiasis

Xin

Cutler

2011

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Section: Vol 18 2011 Vaccine and Antibody Protection Against Candidmentioning

confidence: 99%

“…As a prevention strategy, protection against disease may be actively or passively acquired by vaccination and the transfer of preformed monoclonal antibodies. As a therapeutic measure, experimental evidence indicates that preformed antibodies enhance the effectiveness of antifungal agents (24,43).…”

mentioning

confidence: 99%

Vaccine and Monoclonal Antibody That Enhance Mouse Resistance to Candidiasis

Xin

Cutler

2011

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

“…This protection is associated with enhanced phagocytosis and killing of the fungus (Caesar-TonThat and Cutler, 1997), and the complement system is essential for protection (Han et al, 2001). Later, we found that MAb B6.1 is partially therapeutic at the same dose as the dose that provides full protection (Han, 2010 …”

Section: Introductionmentioning

confidence: 70%

“…In experiments, B6.1 was diluted in DPBS to give an agglutinin titer of 80 (app. 44 µg/mL) against yeast cells, which is the same dose of B6.1, resulting in being prophylactic (Han and Cutler, 1995;Han et al, 2001) and partially therapeutic (Han, 2010). As a negative control antibody, IgM MAb S9 was produced in the same way at the same company.…”

Section: Mabs and Fluconazolementioning

confidence: 99%

Combination immunotherapy of MAb B6.1 with fluconazole augments therapeutic effect to disseminated candidiasis

Lee

Jang

2011

Arch. Pharm. Res.

Self Cite

View full text Add to dashboard Cite

We recently reported that IgM MAb B6.1, specific for β-1, 2-mannotriose on the cell wall of Candida albicans, is therapeutic to disseminated candidiasis due to C. albicans. In the current study, we examined if MAbB6.1 enhances therapeutic effect of fluconazole (FLC) to the disseminated disease. To assess the combination effect, determination by the kidneys-colony forming unit and survival times were used. Results showed that the therapeutic effect of FLC on mice with disseminated candidiasis was dose-dependent, but a FLC dose at 0.8 mg/kg body weight of mice was ineffective. To determine combination effect, mice treated intraperitoneally with a combination of FLC plus MAb B6.1 at 1 h post-infection - a condition of developing partial therapeutic activity - enhanced survival times beyond the effect by only antibody (p < 0.05). The resulting MST (mean survival times) value from the combination-received mice was almost the same as MST value from 3.2 mg FLC dose-given animals (p < 0.05). Another combination of 1.6 mg FLC dose and B6.1 reduced severity of the disseminated disease at almost the same rate as combination efficacy of 0.8 mg FLC dose plus B6.1. This data indicates that B6.1 acts in concert with FLC and that this combination therapy augments protection, which suggests a possibility of reducing FLC dose. The augmentation response was specific because an irrelevant IgM MAb S9 was not effective to the disseminated disease. Thus, our present studies demonstrate that this combination immunotherapy may be a way of solving the problem of limited antifungal drug choices caused by drug-resistant C. albicans.

show abstract

“…Structural analysis revealed that internal antigenic determinants dominate recognition of β-(Man) 3 by IgG3 MAb [73]. β-mannan-specific IgM MAb could also reduce the dose of amphotericin B when used in combination in experimental candidiasis [74]. In contrast to C. neoformans-specific MAbs, complement was found to be essential for the protection by C. albicans β-mannan-specific IgM and IgG3…”

Section: Demonstration Of Protective Role Of Antibodies In Fungal Infmentioning

confidence: 98%

The protective role of immunoglobulins in fungal infections and inflammation

2014

View full text Add to dashboard Cite

International audienceIncreased incidence of fungal infections in the immunocompromised individuals and fungi-mediated allergy and inflammatory conditions in immunocompetent individuals is a cause of concern. Consequently, there is a need for efficient therapeutic alternatives to treat fungal infections and inflammation. Several studies have demonstrated that antibodies or immunoglobulins have a role in restricting the fungal burden and their clearance. However, based on the data from monoclonal antibodies, it is now evident that the efficacy of antibodies in fungal infections is dependent on epitope specificity, abundance of protective antibodies, and their isotype. Antibodies confer protection against fungal infections by multiple mechanisms that include direct neutralization of fungi and their antigens, inhibition of growth of fungi, modification of gene expression, signaling and lipid metabolism, causing iron starvation, inhibition of polysaccharide release, and biofilm formation. Antibodies promote opsonization of fungi and their phagocytosis, complement activation, and antibody-dependent cell toxicity. Passive administration of specific protective monoclonal antibodies could also prove to be beneficial in drug resistance cases, to reduce the dosage and associated toxic symptoms of anti-fungal drugs. The longer half-life of the antibodies and flexibilities to modify their structure/forms are additional advantages. The clinical data obtained with two monoclonal antibodies should incite interests in translating pre-clinical success into the clinics. The anti-inflammatory and immunoregulatory role of antibodies in fungal inflammation could be exploited by intravenous immunoglobulin or IVIg

show abstract

Efficacy of combination immunotherapy of IgM MAb B6.1 and amphotericin B against disseminated candidiasis

Cited by 15 publications

References 30 publications

Vaccine and Monoclonal Antibody That Enhance Mouse Resistance to Candidiasis

Vaccine and Monoclonal Antibody That Enhance Mouse Resistance to Candidiasis

Combination immunotherapy of MAb B6.1 with fluconazole augments therapeutic effect to disseminated candidiasis

The protective role of immunoglobulins in fungal infections and inflammation

Contact Info

Product

Resources

About